Neogen Chemicals Ltd NEOGEN

Summary

Neogen Chemicals is a bromine and lithium specialty-chemicals producer — organolithium compounds, pharma/agro intermediates and custom synthesis — that has spent the last three years building a genuine second business in battery chemicals through its subsidiary Neogen Ionics: electrolyte production licensed from MUIS (a Mitsubishi Chemical/UBE joint venture), and a solid LiPF6 lithium-salt line built with Japan's 100-year-old Morita Chemicals via the 80/20 Neogen Morita New Materials joint venture. Both technology partners are Japanese, not Chinese — a genuine differentiator from several peers in this report reliant on Chinese licensors — and the subsidiary's growth is real: Neogen Ionics generated over 50% of its entire prior-year revenue in a single quarter (Q1 FY27).

The problem is that this scale-up has already cost the company a formal, dated, agency-confirmed setback. On 17 July 2026, CRISIL Ratings downgraded Neogen's bank facilities and NCDs to CRISIL A-/Negative/A2+ from A/Negative/A1, and separately downgraded Neogen Ionics itself from A-/Negative to BBB+/Negative — explicitly citing "battery chemicals project delays and insurance claim issues." This is not a hypothetical qualification-cycle risk of the kind this primer flags generically for the materials layer (§8); it is a primary-source-adjacent, dated confirmation that the ₹1,795 crore Dahej-Pakhajan capex programme has already slipped, with the project cost itself revised upward from an unrecovered original budget.

The financial trail corroborates the downgrade rather than contradicting it. FY26 consolidated PAT fell 17.46% year-on-year despite revenue growth, and Q2 FY26 specifically saw "profit plunges 69% as interest costs surge" — the capex build is pressuring near-term profitability through financing cost well ahead of any offsetting battery-chemicals revenue. Roughly ₹189-251 crore of insurance-claim receivables, likely tied to the same project delays, remain outstanding. None of this has yet been reflected in the stock's extraordinary starting multiple: reported trailing P/E ranges from 137x to 183x depending on source and date, and most third-party target prices found in this research pre-date the July downgrade and should not be relied on without a post-downgrade check.

Net: SELL. The battery-chemicals business is real and the technology partnerships are genuinely non-Chinese, but a company already carrying a confirmed, dated credit-rating consequence of its own capex delays does not deserve a triple-digit earnings multiple, and the market has not yet re-rated it to reflect that.

• Two genuinely non-Chinese technology partnerships. The MUIS (Mitsubishi Chemical/UBE)-licensed electrolyte line and the Neogen Morita New Materials joint venture (80% Neogen / 20% Morita Chemicals, a 100-year-old Japanese lithium-salt producer contributing $20 million) mean Neogen's core process technology does not depend on a Chinese licensor's continued cooperation — a real differentiator from peers exposed to the tightening described in §4 and §7 of this primer.
• The scale-up is real, not promotional. Neogen Ionics generated over 50% of its entire prior-year revenue in Q1 FY27 alone — rapid growth off a small base, but growth that shows up in disclosed quarterly numbers, not just guidance.
• Dual product scope. Neogen covers both electrolyte formulation (MUIS-licensed) and electrolyte salts/LiPF6 (in-house technology plus the Morita JV) — a broader materials-layer footprint than a single-product peer.
• A credible medium-term revenue target with a stated capital-efficiency bar. Management guides battery-chemicals revenue to ₹2,400-2,900 crore by FY29, targeting 18-20% ROCE for that business specifically — a number, not just a direction.
• Some deleveraging already underway. Neogen's first-ever QIP raised approximately ₹600 crore, oversubscribed 6.5x, explicitly used to repay debt and fund working capital.

• A rating agency has already confirmed the project slipped — this is not a forecast, it is a fact on record. CRISIL downgraded Neogen's bank facilities and NCDs to A-/Negative/A2+ from A/Negative/A1 on 17 July 2026, explicitly citing "battery chemicals project delays and insurance claim issues"; subsidiary Neogen Ionics was separately cut from A-/Negative to BBB+/Negative. This is the single clearest, dated, primary-source-adjacent evidence of execution risk found anywhere in this report's materials-layer research.
• The project got more expensive, not less. The combined Dahej Phase 1 (₹428cr) and Pakhajan Phase 2 (₹1,367cr) capex was disclosed as "revised" to a ₹1,795 crore total — the word "revised" implies an increase from an original, lower budget that was not found disclosed, consistent with a cost overrun.
• Profitability is already being squeezed by the capex build, ahead of any offsetting revenue. FY26 consolidated PAT fell 17.46% year-on-year despite revenue growth; Q2 FY26 alone saw profit fall 69% as interest costs surged — a leverage/interest-coverage risk that is compounding, not merely coinciding with, the technology-qualification risk.
• An unresolved contingent asset sits on the balance sheet. Roughly ₹189-251 crore of insurance-claim receivables — plausibly tied to the same project delays — remain outstanding; management "believes" the amount is fully recoverable, but this has not yet been confirmed.
• The valuation has not caught up with the downgrade. A reported trailing P/E of 137-183x is an extraordinary multiple for a company that just received a negative, delay-citing rating action; most third-party target prices found in this research appear to pre-date the July 2026 downgrade and should be treated as stale rather than current until independently re-verified.
• The commercial ramp is still ahead, on an already-revised schedule. Electrolyte commissioning is targeted for H1 FY27 and electrolyte salts separately for H2 FY27 — meaningful revenue contribution remains one to two quarters out even before allowing for further slippage risk.

• CRISIL's next scheduled rating review — the clearest external signal of whether the "Negative" outlook is stabilising or deteriorating further.
• Pakhajan electrolyte commissioning (H1 FY27 target) and salts commissioning (H2 FY27 target) — both already-once-revised milestones; a further slip would corroborate the downgrade's thesis.
• Resolution of the outstanding insurance-claim receivable — full recovery vs. a write-down would materially affect reported earnings quality.
• Deployment of QIP proceeds against stated debt-reduction and working-capital goals.

• Execution risk (dominant, and already partly realised). A rating agency has confirmed delays on the record; this is not a generic industry risk applied by analogy.
• Leverage/interest-coverage risk. Rising financing costs are already visibly compressing profitability during the build-out.
• Valuation risk. A triple-digit P/E leaves minimal margin of safety if execution does not recover quickly.
• Contingent-asset risk. The unresolved insurance receivable is a real, if smaller, source of downside if not recovered as management expects.

FY26 standalone PAT of ₹46.96cr on an implied share count of ~3.0cr (market cap ÷ CMP) gives standalone FY26 EPS of ~₹15.63 — the basis consistent with the reported 137-183x trailing multiple range. Given the confirmed CRISIL downgrade and the rising financing-cost pressure documented above, we apply a deliberately modest forward-growth assumption and a sharply compressed target multiple relative to the current, downgrade-inconsistent trading multiple, rather than assuming a smooth continuation of FY26's already- pressured earnings trajectory:

Base case rounded to ₹1,720. Even our bull case — a 130x multiple, still a rich one — barely clears the current price, which is the point: at 137-183x trailing, the stock is priced for an execution outcome the company's own rating agency has just said is not currently happening on schedule. EV/EBITDA cross-check not performed — FY26 EBITDA was not consistently disclosed across sources in this research. Third-party target prices found (a ₹1,335-2,761 range across 8 analysts, average ~₹1,752.50, per aggregator data) are wide and, per our governance section, likely include pre-downgrade vintage notes; we have not relied on them.

Balance sheet and cash-flow statements are not reproduced here at full granularity. Source: company results coverage and CRISIL Ratings rationale (17 Jul 2026), as aggregated via indianchemicalnews.com, whalesbook.com and scanx.trade (Jul-Sep 2026).